By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
About Fluid Biomed

Investing in the next generation of stents to cure brain aneurysms.

founders
Dr. John Wong
FOUNDER & CEO | LInkedIn
Alim P. Mitha, MD SM
PRESIDENT, CHIEF TECHNOLOGY OFFICER, CO-FOUNDER | LinkedIn
founded
2012
"METIS provided critical resources, advice, and validation to enable our start-up to successively mature into a clinical-stage company with the potential to help patients around the world."
Dr. John Wong |  CEO AND CO-FOUNDER
Fluid Biomed is a medical device company commercializing the first polymer-based brain stent to cure aneurysms. The founders, Dr. John Wong and Dr. Alim Mitha, have worked together for the past two decades helping people suffering from strokes. The company has transitioned their proprietary product, ReSolv, from proof of concept towards final prototyping, validating the unique technology. With the support of its partners, Fluid Biomed is achieving significant scientific, regulatory, and financing milestones along the pathway of product development. Fluid Biomed is well positioned to disrupt the stent market, and ultimately improve the quality of life and well-being of patients.

METIS leverages its extensive in-house medical and corporate expertise to help emerging companies like Fluid Biomed surmount challenges to create the next generation of life-saving technologies.

About Fluid Biomed

Fluid Biomed was founded by two neurosurgeons, Dr. John Wong and Dr. Alim Mitha, at the University of Calgary who have developed a polymer-based stent that can heal a blood vessel by diverting blood flow away from a weak brain aneurysm. Working together for the past two decades to help people with stroke, their drive and commitment to improve patient health sparked a vision to create a radical new stent to cure a wide variety of aneurysms with greater efficiency and safety.

the technology

Brain aneurysms afflict up to 5% of people and can lead to devastating stroke. Fluid Biomed is commercializing the first polymer-based brain stent to cure aneurysms. Their team of neurosurgeons, scientists, and engineers has designed the world’s first hybrid polymer-metal flow-diverting stent to cure this deadly disease. Uniquely constructed of dissolving polymer and metal, this innovative medical device provides a scaffold to allow better healing and visualization of blood vessels.

Their self-expanding stent is engineered to be highly flexible to navigate into delicate blood vessels of the brain. The unique use of polymer in their stent allows better healing of blood vessels while minimizing interference with radiological tests. As the company founders are academic specialists as well as practicing neurosurgeons, they are optimizing the medical device for patient safety, treatment efficacy, and physician ease-of-use.

Looking Ahead

Fluid Biomed has begun an international First-in-Human clinical trial to validate the technology. With the support of its partners, Fluid Biomed is achieving significant scientific, regulatory, and financing milestones along the pathway of product development. Fluid Biomed is well positioned to disrupt the stent market, and ultimately improve the quality of life and well-being of patients everywhere.